In summer 2009, US Food and Drug Administration commissioner Margaret Hamburg reversed existing, sound policy that required prior legal review of regulatory letters (untitled and warning letters) by the FDA’s Office of Chief Counsel. This reversal – eliminating review of regulatory letters for legal integrity except in cases of “significant legal issues” – is one of several changes instituted by Dr Hamburg to increase enforcement activity and purportedly to limit enforcement delays1,2...
Please login to read the full article.
